B-type natriuretic peptide-guided heart failure therapy: A meta-analysis

Archives of Internal Medicine

Volumn 170, Issue 6, 2010, Pages 507-514

  Porapakkham, Pramote ^a   Porapakkham, Pornwalee ^a   Zimmet, Hendrik ^a   Billah, Baki ^a   Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; ISOSORBIDE DINITRATE; METOLAZONE; SPIRONOLACTONE;

CLINICAL TRIAL; COMPARATIVE STUDY; HEART FAILURE; HOSPITALIZATION; HUMAN; META ANALYSIS; MORTALITY; OUTPATIENT DEPARTMENT; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

EID: 77951059915     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.35     Document Type: Review

References (43)

1. Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J. 1999;137(2):352-360.
2. de Groote P, Isnard R, Clerson P, et al. Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology: the Impact-Reco Programme. Eur J Heart Fail. 2009;11(1):85-91.
3. Dickstein K, Cohen-Solal A, Filippatos G, et al; Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology; ESC Committee for Practice Guidelines; Document Reviewers. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29(19): 2388-2442.
4. Hunt SA, Abraham WT, Chin MH, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154-e235.
5. Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep. 2000;2(3):198-205.
6. Jankowski M. B-type natriuretic peptide for diagnosis and therapy. Recent Pa Cardiovasc Drug Discov. 2008;3(2):77-83.
7. Worster A, Balion CM, Hill SA, et al. Diagnostic accuracy of BNP and NT-proBNP in patients presenting to acute care settings with dyspnea: a systematic review. Clin Biochem. 2008;41(4-5): 250-259. (Pubitemid 351249854)
8. Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med. 2002; 39(2):131-138. (Pubitemid 34118942)
9. Valle R, Aspromonte N, Carbonieri E, et al. Fall in readmission rate for heart failure after implementation of B-type natriuretic peptide testing for discharge decision: a retrospective study. Int J Cardiol. 2008;126(3):400-406. (Pubitemid 351636361)
10. van Veldhuisen DJ, Genth-Zotz S, Brouwer J, et al. High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol. 1998;32 (7):1811-1818. (Pubitemid 29010439)
11. Latini R, Masson S, Anand I, et al; Valsartan Heart Failure Trial Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2002;106(19):2454-2458.
12. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001; 37(5):1228-1233. (Pubitemid 32295579)
13. Kawai K, Hata K, Takaoka H, Kawai H, Yokoyama M. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. Am Heart J. 2001;141(6):925-932. (Pubitemid 32477003)
14. Li N, Wang JA. Brain natriuretic peptide and optimal management of heart failure. J Zhejiang Univ Sci B. 2005;6(9):877-884. (Pubitemid 41443861)
15. Berlin JA; University of Pennsylvania Meta-analysis Blinding Study Group. Does blinding of readers affect the results of meta-analyses? Lancet. 1997;350(9072):185-186.
16. National Library of Medicine Medical Subject Headings Web site. http://www.nlm.nih.gov/mesh/. Accessed December 18, 2008.
17. Murdoch DR, McDonagh TA, Byrne J, et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J. 1999; 138(6, pt 1):1126-1132.
18. Shah M; STARBRITE Investigators. STARBRITE: a randomized pilot trial of BNP-guided therapy in patients with advanced heart failure [abstract 2554]. Circulation. 2006;114:II528.
19. Berger R, Moertl D, Huelsmann M, et al. BNP guided care by a heart failure specialist in addition to home-based nurse care in patients with chronic heart failure: a three-arm, prospective, randomized study. J Am Coll Cardiol. 2006;47(suppl A):89A.
20. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement: quality of reporting of meta-analyses. Lancet. 1999;354(9193):1896- 1900.
21. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355(9210):1126-1130. (Pubitemid 30172933)
22. Beck-da-Silva L, de Bold A, Fraser M, Williams K, Haddad H. BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure. Congest Heart Fail. 2005;11(5):248-253.
23. Esteban F, Anguita M, Castillo J, et al. BNP levels-guided therapy for heart failure: a comparative study against usual clinical monitoring: ESC 2006. Eur Heart J Suppl. 2006(suppl):1416.
24. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007;49(16): 1733-1739.
25. Pfisterer M, Buser P, Rickli H, et al; TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383-392.
26. Richards A, Lainchbury J, Troughton R, et al. NTproBNP guided treatment for chronic heart failure: results from the BATTLESCARRED Trial: American Heart Association Inc [abstract 5946]. Circulation. 2008;118:S1035-S1036.
27. PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart failure morbidity And mortality Study. Paper presented as a late-breaking clinical trial at: Annual Scientific Meeting of American College of Cardiology; March 29, 2009; Orlando, Florida.
28. SIGNAL-HF Study. Paper presented as a late-breaking clinical trial at the European Heart Failure Association Annual Meeting; June 1, 2009; Nice, France.
29. Lainchbury JG, Troughton RW, Frampton CM, et al. NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail. 2006; 8(5):532-538.
30. Friesewinkel O, Furrer M, Hanggi G, Rutschmann A. Severe heart failure: treatment optimization and monitoring using plasma NT-proBNP levels: a useful tool in clinical practice [in German]. Praxis (Bern 1994). 2004;93(12):476-480.
31. Mant D, Hobbs FR, Glasziou P, et al. Identification and guided treatment of ventricular dysfunction in general practice using blood B-type natriuretic peptide. Br J Gen Pract. 2008;58(551):393-399. (Pubitemid 351780894)
32. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009;158(3):422-430.
33. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302.
34. Hjalmarson A, Goldstein S, Fagerberg B, et al; MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000;283(10):1295-1302.
35. Pitt B, Zannad F, Remme WJ, et al; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341(10):709-717.
36. Lustgarten J. Cancer, aging and immunotherapy: lessons learned from animal models. Cancer Immunol Immunother. 2009;58:1979-1989.
37. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest. 2009;135(1):173-180.
38. Premoli A, Paschetta E, Hvalryg M, Spandre M, Bo S, Durazzo M. Characteristics of liver diseases in the elderly: a review. Minerva Gastroenterol Dietol. 2009;55(1):71-78.
39. Wang TJ, Larson MG, Levy D, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 2002;90(3):254-258.
40. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40(5):976-982. (Pubitemid 34994995)
41. Schou M, Gustafsson F, Videbaek L, et al. Design and methodology of the North Star Study: NT-proBNP stratified follow-up in outpatient heart failure clinics: a randomized Danish multicenter study. Am Heart J. 2008;156(4):649-655.
42. PROTECT Investigators. The use of pro-brain natriuretic peptide targeted therapy to tailor medical management of patients with congestive heart failure followed in an outpatient setting: the ProBNP Outpatient Tailored CHF Therapy (PROTECT) Study. ClinicalTrials.gov/ct2/show/NCT00351390?term =PROTECT&rank=8. Accessed December 18, 2009.
43. EXIMPROVECHF Investigators. Improvement in clinical outcomes of patients with chronic heart failure using serial NT-proBNP monitoring: the Ex-IMPROVE-CHF Study. ClinicalTrials.gov/ct2/show /NCT000601679?term=the+EX-IMPROVE +Study&rank=1. Accessed December 18, 2008.